-
Mashup Score: 0Ocrelizumab Controls Disease Progression in Phase 3b Open-Label Study - Practical Neurology - 3 year(s) ago
In an open-label phase 3b study (NCT03085810), 85% of people who used ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) as their first treatme
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 6Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab - 4 year(s) ago
Objective To describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS. Methods Two case reports with 1 year of follow-up and retrospective longitudinal measurements of serum neurofilament light (NfL) levels and B-cells. Results PML was diagnosed 78 days (case 1) and 97 days…
Categories: Latest Headlines, NeurologyTweet-
Via @GreenJournal: The clinical course of carryover #progressivemultifocalleukoencephalopathy (#PML) after switching from #natalizumab to #ocrelizumab in 2 #patients with relapsing-remitting #multiplesclerosis was mild in both patients. @amsterdamumc https://t.co/FhaTXwlsni https://t.co/9V7oPCOtlg
-
-
Mashup Score: 0Study Examining Ocrelizumab Treatment in African-Americans, Hispanic- and Latinx-Americans Is Actively Enrolling - Practical Neurology - 4 year(s) ago
A new study to characterize the response to ocrelizumab (Ocrevus; Genentech, South San Francisco, CHIMES (NCT04377555) in individuals from traditional
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet-
Study Examining #Ocrelizumab Treatment in #African-Americans, #Hispanic and Latinx-Americans Is Actively Enrolling #PracticalNeurology #neurology https://t.co/2HSrD7adDb
-
-
Mashup Score: 0Data Show Ocrelizumab Reduces Disability Progression and Disease Risk in MS - Practical Neurology - 4 year(s) ago
Post hoc analysis of data from phase 3 Opera 1 (NCT01247324) and Opera 2 (NCT01298492) studies, including the open-label extensions, suggests oc
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet-
Data Show #Ocrelizumab Reduces Disability Progression and Disease Risk in #MS PracticalNeurology #neurology #multiplesclerosis https://t.co/F8Z4G3vxtR
-
-
Mashup Score: 1Regulatory Agencies Consider 2-Hour Infusion Times for Ocrelizumab - Practical Neurology - 4 year(s) ago
The US Food and Drug Administration (FDA) has accepted and will review a supplemental Biologics License Application (sBLA) for ocrelizumab (Ocrevus; G
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet-
Regulatory Agencies Consider 2-Hour Infusion Times for #Ocrelizumab - #PracticalNeurology #neurology #multiplesclerosis @genentech https://t.co/oO02QFFha0
-
#Ocrelizumab Controls Disease Progression in Phase 3b Open-Label Study #neurology #MS #movementdisorder #PracticalNeurology https://t.co/AUzChlycxt